Midatech Divests US Unit To Focus On Its Rival Drug To Novartis' Sandostatin LAR
Executive Summary
UK-based Midatech will use money from its US divestment to ramp up R&D efforts and progress its key oncology product MTD201, which has a favorable clinical profile versus Novartis' blockbuster Sandostatin LAR, the biotech's CEO tells Scrip.
You may also be interested in...
Back From The Dead Biodexa Makes Bid For VarianBio
Having just avoided going into administration, the firm formerly known as Midatech has pivoted its business model from a drug delivery company to a therapeutics player and has hit the acquisition trail.
Midatech Survival Plan Scuppered By Shareholders
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.
Midatech Bets on Bioasis Merger For Survival
With just enough cash to stay afloat until the first quarter, Midatech is linking up with US-based, Canada-listed Bioasis to create a new rare disease player, Biodexa.